Clinical Response to Seribantumab, an Anti–Human Epidermal Growth Factor Receptor-3 Immunoglobulin 2 Monoclonal Antibody, in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma Harboring an <i>NRG1</i> Fusion
Subotheni Thavaneswaran(The University of Sydney), David M. Thomas(New South Wales Department of Health), Valerie M. Jansen(New York Oncology Hematology), Wei Yen Chan(Melanoma Institute Australia), Ray Asghari(Bankstown Lidcombe Hospital), John P. Grady(Garvan Institute of Medical Research), Maegan Deegan(New York Oncology Hematology)
Cited by 8
Related Papers
Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial
|The Lancet|2019|472
Reporting, Appraising, and Integrating Data on Genotype Prevalence and Gene-Disease Associations
|American Journal of Epidemiology|2002|372
Li-Fraumeni syndrome: cancer risk assessment and clinical management
|Nature Reviews Clinical Oncology|2014|276
Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients With Osteosarcoma
|JAMA Oncology|2020|251
Monogenic and polygenic determinants of sarcoma risk: an international genetic study
|The Lancet Oncology|2016|213